Ezetimibe’s Secret Identity? A Possible New Angle on Alzheimer’s Prevention
In this YouTube video, a self‑identified brain scientist enthusiastically presents recent research suggesting that ezetimibe—a cholesterol‑lowering medication—may have a previously unknown role in protecting the brain from Alzheimer’s disease. The speaker explains that researchers performed a blind screen of existing drugs for the ability to inhibit pathological protein aggregation, a hallmark of neurodegenerative disorders such as Alzheimer’s and Parkinson’s. Ezetimibe emerged as a top hit, surprising the investigators. The drug is reported to cross the blood‑brain barrier and to interfere with the interaction between the scaffold protein 14‑3‑3 and the metabolic enzyme hexokinase, leading to reduced amyloid‑β and tau clumping in experimental models. Additionally, a retrospective chart review of human patients showed an association with roughly an eight‑fold lower risk of developing Alzheimer’s among ezetimibe users. The presenter emphasizes that this is not a cholesterol‑centric story but rather a potential “secret identity” for ezetimibe, framing the findings as exciting yet preliminary, and urges viewers to consider the possibility that a common medication could have a novel neuroprotective function.
